共 66 条
[1]
Van Deun A(2010)Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis Am J Respir Crit Care Med 182 684-692
[2]
Moher D(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 264-9
[3]
Richardson WS(1995)The well-built clinical question: a key to evidence-based decisions ACP J Club 123 A12-3
[4]
Laserson KF(2005)Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis Int. J. Tuberc. Lung Dis 9 640-645
[5]
Mukherjee JS(2003)Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from lima, Peru Int. J. Tuberc. Lung Dis 7 637-44
[6]
Loveday M(2015)Community-based care vs. Centralised hospitalisation for MDRTB patients, KwaZulu-Natal, South Africa Int. J. Tuberc. Lung Dis 9 163-71
[7]
Ganzaya S(2013)Countrywide audit of multidrug-resistant tuberculosis and treatment outcomes in Mongolia Public Health Action 3 333-6
[8]
Garcia-Garcia Ma DL(2001)Drug resistance of Mycobacterium tuberculosis in Orizaba, Veracruz. Implications for the tuberculosis prevention and control program Rev Investig Clin 53 315-23
[9]
Dave P(2015)Has introduction of rapid drug susceptibility testing at diagnosis impacted treatment outcomes among previously treated tuberculosis patients in Gujarat, India? PLoS One 10 e0121996-14
[10]
Ahmad N(2015)Management and treatment outcomes of MDR-TB: Results froma setting with high rates of drug resistance Int. J. Tuberc. Lung Dis 19 1109-31